Class I Phosphatidylinositol 3-Kinases
-
Subject Areas on Research
-
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
-
Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.
-
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.
-
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
-
Comprehensive molecular portraits of human breast tumours.
-
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
-
Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels.
-
Genetic heterogeneity of diffuse large B-cell lymphoma.
-
High frequency of mutations of the PIK3CA gene in human cancers.
-
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
-
Leukaemia hijacks a neural mechanism to invade the central nervous system.
-
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA.
-
Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
-
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
-
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
-
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
-
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism.
-
PIK3CA mutation in a mixed dysembryoplastic neuroepithelial tumor and rosette forming glioneuronal tumor, a case report and literature review.
-
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.
-
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer.
-
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
-
Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism.
-
Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3-kinase complex.
-
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
-
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
-
The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.